Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction
Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction
Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in
 energy homeostasis and glucose metabolism by regulating islet hormone secretion,
 gastrointestinal motility, and food intake, making GLP-1 agonist a treatment for diabetes and
 obesity. Pre-clinical and clinical studies have demonstrated that GLP-1 also has
 cardio-protection effects. GLP-1 agonists is able to improve markers of cardiac function,
 reduce myocardial infarct size and post-myocardial infarction remodeling in experimental
 myocardial infarction. And GLP-1 infusion improved left ventricular function and increases
 myocardial salvage in patients with acute myocardial infarction (AMI). The investigators'
 previous study found that GLP-1 analogues attenuated ischemia-reperfusion induced apoptosis
 of stem- and myocardial microvascular endothelial cells, and liraglutide (a GLP-1 analog)
 usage during hospital stay can prevent no-reflow and improve heart function in AMI.
 Therefore, the investigators carried out a cohort study to evaluate the association between
 plasma GLP-1 and in-hospital complications in patients with ST-segment elevation myocardial
 infarction.
Inclusion Criteria:

 -  a diagnosis of STEMI and needed PCI

 Exclusion Criteria:

 -  patients with cancer patients who used DPP4 inhibitor patients who used GLP1 analogue